Skip to main content

Case Study 3

Pharmaceutical Industry

Skimune®Pharm is designed to predict first-in-man hypersensitivity or adverse immune reactions in response to small or large molecule therapeutics.

Our client, a global pharmaceutical company requested Alcyomics to determine human in vitro responses to a number of small molecule drugs known to be associated or not associated with adverse immune reactions. The study, involving the use of Skimune®Pharm, was performed blinded to outcome. Results showed a positive response to phenobarbital (grade III response) and a negative response to metformin and sulphamethoxazole (see Figure1). A 0.86 correlation coefficient between Skimune®Pharm results and clinical outcome was determined. The high correlation to clinical outcome indicates the strong predictive capacity of the Skimune®Pharm assay and how it can be used as a pre-clinical tool to determine immunotoxicity of therapeutic drugs.

Figure 1  Histopathological analysis of the adverse effects  of small molecule drugs. Skin incubated with phenobarbital showing a grade III positive response, metformin and sulphamethoxazole showing a grade I negative response (B,C respectively). In the positive biopsy (A) arrows point to vacuolisation of keratinocytes and cleft formation.

  • This form collects your name and email so what we can add your to our newsletter list and send you relevant updates via email. Read our privacy policy for details on how we manage your data.